EuroAPI responds to Brindisi rumours

EuroAPI has responded to local media speculation about the sale of its Brindisi site in Italy by stating it is “engaged in discussions with potential buyers” but no decision as yet been made. Brindisi, which produces 11 APIs and intermediates, mostly anti-infectives, ceased production in March 2024, after an internal audit identified quality control deficiencies due to potential local misconduct.

“As previously communicated, the review of strategic options for certain industrial assets is progressing in line with the group’s Focus-27 transformation plan, with the objective of completing the related processes by the end of 2027,” the firm said. “EuroAPI will communicate in accordance with applicable regulatory obligations should any transaction materialise.”